40.39
-1.38 (-3.29%)
| Penutupan Terdahulu | 41.76 |
| Buka | 42.00 |
| Jumlah Dagangan | 11,091 |
| Purata Dagangan (3B) | 18,947 |
| Modal Pasaran | 112,504,000 |
| Harga / Jualan (P/S) | 5.95 |
| Harga / Buku (P/B) | 4.33 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Nov 2025 |
| Margin Keuntungan | -107.77% |
| Margin Operasi (TTM) | -879.63% |
| EPS Cair (TTM) | -4.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 121.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.84% |
| Nisbah Semasa (MRQ) | 5.12 |
| Aliran Tunai Operasi (OCF TTM) | -13.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.91 M |
| Pulangan Atas Aset (ROA TTM) | -26.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Sol-Gel Technologies Ltd. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 3.5 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.80 |
|
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 70.00% |
| % Dimiliki oleh Institusi | 24.29% |
| Julat 52 Minggu | ||
| Median | 50.00 (23.81%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Oct 2025 | 50.00 (23.81%) | Beli | 39.81 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 40.23 | - | 7,813 | 306,854 |
| Jumlah Keseluruhan Kuantiti Bersih | 7,813 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 306,854 | |||
| Purata Pembelian Keseluruhan ($) | 40.23 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 03 Dec 2025 | Beli (+) | 2,524 | 39.78 | 100,405 | |
| OPALEYE MANAGEMENT INC. | 01 Dec 2025 | Beli (+) | 4,340 | 38.67 | 167,828 | |
| OPALEYE MANAGEMENT INC. | 26 Nov 2025 | Beli (+) | 943 | 40.69 | 38,371 | |
| OPALEYE MANAGEMENT INC. | 24 Nov 2025 | Beli (+) | 6 | 41.76 | 251 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Nov 2025 | Pengumuman | Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |